Adding Pluvicto to standard therapy in metastatic patients led to a radiographic PFS benefit, but questions remain about whether the agent belongs in the first-line setting. Medscape Medical News
Adding Pluvicto to standard therapy in metastatic patients led to a radiographic PFS benefit, but questions remain about whether the agent belongs in the first-line setting. Medscape Medical News